These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11979388)

  • 1. Comparison of insulinotrophic actions of nateglinide with glibenclamide dissociated from absorption in conscious dogs.
    Okamoto M; Ogihara N; Kawamura W; Ebihara S; Takiguchi K; Morita T; Uchida R; Yamaguchi J; Sakai T; Okuda Y; Hayashi Y; Arakawa Y; Kikuchi M
    Metabolism; 2002 May; 51(5):575-81. PubMed ID: 11979388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
    Hu S; Wang S; Fanelli B; Bell PA; Dunning BE; Geisse S; Schmitz R; Boettcher BR
    J Pharmacol Exp Ther; 2000 May; 293(2):444-52. PubMed ID: 10773014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.
    Sunaga Y; Gonoi T; Shibasaki T; Ichikawa K; Kusama H; Yano H; Seino S
    Eur J Pharmacol; 2001 Nov; 431(1):119-25. PubMed ID: 11716850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mechanisms underlying the unique pharmacodynamics of nateglinide.
    Hu S; Boettcher BR; Dunning BE
    Diabetologia; 2003 Mar; 46 Suppl 1():M37-43. PubMed ID: 12652357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics, insulinotropic action and hypoglycemic effect of nateglinide and glibenclamide in normal and diabetic rats.
    Courtois P; Jijakli H; Ladriere L; Oguzhan B; Sener A; Malaisse WJ
    Int J Mol Med; 2003 Jan; 11(1):105-9. PubMed ID: 12469228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin secretion from isolated rat islets induced by the novel hypoglycemic agent A-4166, a derivative of D-phenylalanine.
    Tsukuda K; Sakurada M; Niki I; Oka Y; Kikuchi M
    Horm Metab Res; 1998 Jan; 30(1):42-9. PubMed ID: 9503038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects.
    Karara AH; Dunning BE; McLeod JF
    J Clin Pharmacol; 1999 Feb; 39(2):172-9. PubMed ID: 11563410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.
    Tuomi T; Honkanen EH; Isomaa B; Sarelin L; Groop LC
    Diabetes Care; 2006 Feb; 29(2):189-94. PubMed ID: 16443858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.
    Malaisse WJ
    Treat Endocrinol; 2003; 2(6):401-14. PubMed ID: 15981944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
    Kikuchi M
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.
    McLeod JF
    Clin Pharmacokinet; 2004; 43(2):97-120. PubMed ID: 14748619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel enhancer of insulinotrophic action by high glucose (JTT-608) stimulates insulin secretion from pancreatic beta-cells via a new cellular mechanism.
    Itabashi N; Okada K; Muto S; Fujita N; Ohta T; Miyazaki Ji ; Asano Y; Saito T
    J Pharmacol Exp Ther; 2001 Jun; 297(3):953-60. PubMed ID: 11356916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the rapidity of onset of the therapeutic effect between nateglinide and mitiglinide by PK/PD analysis in rats.
    Takanohashi T; Arisaka H; Ubukata K; Hayashi M; Yamada Y
    Eur J Drug Metab Pharmacokinet; 2012 Mar; 37(1):9-15. PubMed ID: 22012638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Structures and mechanisms for non SU insulin secretagogues].
    Kikuchi M
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():362-70. PubMed ID: 12387019
    [No Abstract]   [Full Text] [Related]  

  • 15. Insulin exocytosis in Goto-Kakizaki rat beta-cells subjected to long-term glinide or sulfonylurea treatment.
    Kawai J; Ohara-Imaizumi M; Nakamichi Y; Okamura T; Akimoto Y; Matsushima S; Aoyagi K; Kawakami H; Watanabe T; Watada H; Kawamori R; Nagamatsu S
    Biochem J; 2008 May; 412(1):93-101. PubMed ID: 18254725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics.
    Müller G; Hartz D; Pünter J; Okonomopulos R; Kramer W
    Biochim Biophys Acta; 1994 May; 1191(2):267-77. PubMed ID: 8172912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action.
    Hu S
    Eur J Pharmacol; 2002 May; 442(1-2):163-71. PubMed ID: 12020694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide.
    Ikenoue T; Okazaki K; Fujitani S; Tsuchiya Y; Akiyoshi M; Maki T; Kondo N
    Biol Pharm Bull; 1997 Apr; 20(4):354-9. PubMed ID: 9145209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of D-phenylalanine-derivative hypoglycemic agent A-4166 on pancreatic alpha- and beta-cells: comparative study with glibenclamide.
    Hirose H; Maruyama H; Seto Y; Ito K; Fujita T; Dan K; Kanda N; Saruta T; Kato R
    Pharmacology; 1995 Mar; 50(3):175-81. PubMed ID: 7746834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.
    Kalbag JB; Walter YH; Nedelman JR; McLeod JF
    Diabetes Care; 2001 Jan; 24(1):73-7. PubMed ID: 11194245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.